# OnCo record ivermectin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ivermectin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ivermectin" ;
  schema:name "Ivermectin"@en ;
  schema:alternateName "Stromectol"@en, "IVM"@en, "MK-0933"@en, "Stromectol" ;
  schema:description "Ivermectin is a worm and parasite medicine that is being tested as an add-on to immunotherapy in two small early trials. No trial has shown that it treats any cancer, and people who have dosed themselves outside a trial have ended up in hospital with seizures or liver damage."@en ;
  schema:url <https://onco.cc/drugs/ivermectin/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ivermectin> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050742>, <https://list.essentialmeds.org/medicines/58>, <https://clinicaltrials.gov/study/NCT05318469>, <https://clinicaltrials.gov/study/NCT07487805>, <https://clinicaltrials.gov/study/NCT04447235>, <https://clinicaltrials.gov/study/NCT02366884>, <https://www.fda.gov/consumers/consumer-updates/products-claiming-cure-cancer-are-cruel-deception>, <https://doi.org/10.1007/s11912-025-01704-z>, <https://doi.org/10.1038/s41523-021-00229-5>, <https://doi.org/10.1038/s41523-026-00988-z>, <https://doi.org/10.3390/nursrep13010030>, <https://doi.org/10.21873/anticanres.18194>, <https://doi.org/10.21873/anticanres.18276>, <https://doi.org/10.1016/j.gore.2025.101803>, <https://doi.org/10.1016/j.gore.2025.101920>, <https://doi.org/10.1080/00325481.2026.2672183>, <https://doi.org/10.7759/cureus.108896>, <https://doi.org/10.1080/15563650.2022.2134788>, <https://doi.org/10.1001/jamanetworkopen.2026.16780>, <https://doi.org/10.1002/jat.70166>, <https://en.wikipedia.org/wiki/Ivermectin> ;
  onco:status "phase-2" ;
  onco:modality "Oral antiparasitic small molecule (macrocyclic lactone), studied in cancer as an add-on to checkpoint antibodies" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/fenbendazole-ivermectin-repurposing-claims/>, <https://onco.cc/technologies/drug-repurposing/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/balstilimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/mebendazole/>, <https://onco.cc/drugs/fenbendazole/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/agenus/> ;
  onco:institutions <https://onco.cc/institutions/cedars-sinai-cancer/>, <https://onco.cc/institutions/uf-health-cancer-center/> ;
  onco:terms <https://onco.cc/terms/off-label/>, <https://onco.cc/terms/preclinical/>, <https://onco.cc/terms/in-vitro-in-vivo/>, <https://onco.cc/terms/cell-line/>, <https://onco.cc/terms/rp2d/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/hepatotoxicity/>, <https://onco.cc/terms/trial-phases/>, <https://onco.cc/terms/pharmacokinetics/>, <https://onco.cc/terms/single-arm/> ;
  onco:trials <https://onco.cc/trials/nct05318469/>, <https://onco.cc/trials/nct07487805/>, <https://onco.cc/trials/nct04447235/>, <https://onco.cc/trials/nct02366884/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-misinformation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-patel-ivermectin-cancer-curr-oncol-rep-2025/>, <https://onco.cc/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/>, <https://onco.cc/key-papers/paper-straughn-ivermectin-hope-versus-hype-2025/>, <https://onco.cc/key-papers/paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026/>, <https://onco.cc/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/>, <https://onco.cc/key-papers/paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026/>, <https://onco.cc/key-papers/paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026/>, <https://onco.cc/key-papers/paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026/>, <https://onco.cc/key-papers/paper-powderly-fenbendazole-ivermectin-liver-injury-2026/>, <https://onco.cc/key-papers/paper-hoang-ivermectin-toxicity-clin-toxicol-2022/>, <https://onco.cc/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/>, <https://onco.cc/key-papers/paper-ghai-california-poison-control-ivermectin-2024/>, <https://onco.cc/key-papers/paper-jimenez-gaona-ivermectin-loja-ecuador-2023/>, <https://onco.cc/key-papers/paper-juarez-ivermectin-repositioned-cancer-drug-2018/>, <https://onco.cc/key-papers/paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021/>, <https://onco.cc/key-papers/paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026/>, <https://onco.cc/key-papers/paper-ishiguro-dichloroacetate-ivermectin-cureus-2022/>, <https://onco.cc/key-papers/paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026/> .